anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
FIELD: medicine, virology, biotechnology. SUBSTANCE: method involves infection of cellular culture Vero with measles virus, virus passage through cellular culture, culture keeping at temperature 6-8 C for 48-72 h and extraction of antigen fraction with 1.5-3% solution of sodium octylglycopyranoside. Invention provides preparing the enriched fraction of surface antigens of measles virus. Invention can be used for preparing novel immunogenic and diagnostic preparations. EFFECT: improved preparing method, valuable properties of fraction. 2 tbl
Participants with metastatic castration resistant prostate cancer (mCRPC) will be evaluated for genetic polymorphism and pharmacodynamic parameters from serum and plasma samples collected during the Abira-DES study (NCT02217566). Serum and plasma samples were collected after use of diethylstilbestrol (DES) and subsequent abiraterone acetate therapy. Peripheral blood samples were collected prior to initiation of abiraterone acetate therapy, after 12 weeks of therapy, and at the time of disease progression (evaluated by prostate specific antigen \[PSA\] response).
Chronic primary low back pain (CPLBP) refers to low back pain that persists over 3 months, that cannot be explained by another chronic condition, and that is associated with emotional distress and disability. Previous studies have shown that spinal manipulative therapy (SMT) is effective in relieving CPLBP, but the underlying mechanisms remain elusive. This randomized placebo-controlled dual-blind mixed experimental trial (NCT05162924) aimed to investigate the efficacy of SMT to improve CPLBP and its underlying mechanisms. Ninety-eight individuals with CPLBP and 49 controls were recruited. Individuals with CPLBP received SMT (n = 49) or a control intervention (n = 49), 12 times over 4 weeks. The primary outcomes were CPLBP intensity (0-100 on a numerical rating scale) and disability (Oswestry Disability Index). Secondary outcomes included pressure pain thresholds in 4 body regions, pain catastrophizing, Central Sensitization Inventory, depressive symptoms, and anxiety scores. Individuals with CPLBP showed widespread mechanical hyperalgesia (P < .001) and higher scores for all questionnaires (P < .001). SMT reduced pain intensity compared with the control intervention (mean difference: -11.7 [95% confidence interval, -11.0 to -12.5], P = .01), but not disability (P = .5). Similar mild to moderate adverse events were reported in both groups. Mechanical hyperalgesia at the manipulated segment was reduced after SMT compared with the control intervention (P < .05). Pain catastrophizing was reduced after SMT compared with the control intervention (P < .05), but this effect was not significant after accounting for changes in clinical pain. Although the reduction of segmental mechanical hyperalgesia likely contributes to the clinical benefits of SMT, the role of pain catastrophizing remains to be clarified. PERSPECTIVE: This randomized controlled trial found that 12 sessions of SMT yield greater relief of CPLBP than a control intervention. These clinical effects were independent of expectations, and accompanied by an attenuation of hyperalgesia in the targeted segment and a modulation of pain catastrophizing.
ABSTRACT OF THE DISCLOSURE     The present invention provides a fast, efficient and precise method and apparatus for compounding a large  number of solutions for use in hyperalimentation therapy.  The apparatus includes a host computer (4) which maintains a data base of prescriptions to be compounded, and a high speed compounding apparatus (8) connected to the host computer (4) for compounding mixtures of base solutions in response to information supplied by the host computer from the prescription data base.         Information can be entered concerning patients or prescriptions through a display into the host computer data base.  The host computer also includes provisions for a library of prestored standard prescriptions which can be recalled and associated with a given patient.  A group of prescriptions to be compounded is first sorted in accordance with the types of specified base solutions and optionally sorted again based on the concentration of base solutions.  The prescription information is transmitted to the compounding apparatus in sorted order thereby minimizing the required number of containers of base solution.
The invention discloses application of miR-296-3p to preparation of a kit for diagnosing prostate cancer generation or migration. Researches show that miR-296-3p acts on a target gene CDH1 (cadherin) of miR-296-3p to ensure that the transcription is inhibited or degraded, E-cadherin expression is reduced, so that the prostate cancer migration invasion is promoted. After the miR-296-3p is over-expressed, the expression level of the E-cadherin is reduced, adhesion among tumor cells is weakened, and migration invasion capacity is improved. Therefore, through detecting the expression of the E-cadherin and miRNA-296-3p, the prostate cancer migration can be diagnosed and pathologically graded, and migration and prognosis are evaluated. A tumor migration intervention strategy can be designed according to the characteristic that the miR-296-3p targets the E-cadherin, and the application of anti-miR-296-3p to the preparation of drugs for inhibiting the prostate cancer invasion migration is provided. The invention has an important practical significance and a huge potential application value in the fields of medicines and bio-pharmaceuticals.
Mast cells (MCs) play a significant role in various diseases, and their activation and degranulation can trigger inflammatory responses and barrier damage. Several studies have indicated that vagus nerve stimulation (VNS) exerts ameliorates neurological injury, and regulates gut MC degranulation. However, there is limited research on the modulatory effect of VNS on MCs in both the gut and brain in brain ischemia-reperfusion (I/R) injury in this process. We aim to develop a minimally invasive, targeted and convenient VNS approach to assess the impact of VNS and to clarify the relationship between VNS and MCs on the prognosis of acute ischemic stroke. We utilized middle cerebral artery occlusion/reperfusion (MCAO/r) to induce brain I/R injury. After the experiment, the motor function and neurofunctional impairments of the rats were detected, and the gastrointestinal function, blood-brain barrier (BBB) and intestinal barrier damage, and systemic and local inflammation were evaluated by Nissl, TTC staining, Evans blue, immunofluorescence staining, transmission electron microscopy, western blot assays, ELISA, and fecal 16S rRNA sequencing methods. Our research confirmed that our minimally invasive VNS method is a novel approach for stimulating the vagus nerve. VNS alleviated motor deficits and gastrointestinal dysfunction while also suppressing intestinal and neuroinflammation. Additionally, VNS ameliorated gut microbiota dysbiosis in rats. Furthermore, our analysis indicated that VNS reduces chymase secretion by modulating MCs degranulation and improves intestinal and BBB damage. Our results showed that VNS treatment can alleviate the damage of BBB and colonic barrier after cerebral I/R by modulating mast cell degranulation, and alleviates systemic inflammatory responses.
Throughout the intervention phase, participants will attend weekly intervention visits. During these visits, an occupational therapist (OT) will educate the participant and their caregiver on the therapy plan which includes the iPad apps to be completed during the week. The participants will be asked to complete their therapy plan for 1 hour per day at home, 4 days per week.
FIELD: medicine, veterinary science. ^ SUBSTANCE: invention refers to veterinary medicine. A method consists in the fact that a solution heated to 30-35C is rubbed in acupuncture points. For preparing the solution, iodine crystals - 0.6 g, potassium iodide - 0.6 g, ground paraffin - 13.0 g are pre-dissolved in chloroform - 75.0 ml and drawn at room temperature for 48-72 hours in a dark glass vessel with a ground cover. The acupuncture point is treated for 3-30 minutes. ^ EFFECT: method provides longer exposure on biologically active points, allows preserving hair coat, reducing tissue damage and animal's anxiety. ^ 3 ex
A placebo-controlled study that will enroll male and female tobacco smokers' menthol to participate in five experimental sessions. During the experimental session, subjects will be given an IV infusion of either saline or 1 mg nicotine at rapid, moderate or slow infusion rates (nicotine at 0.24,0.096, 0.048 and 0.024, mcg per kg body weight per sec). The infusion conditions for each experimental session will be determined in random order. Aim 1 is to establish a dose-effect curve for positive subjective effects (drug liking and good drug effects) and alleviation of smoking urges, as a function of nicotine delivery rate in menthol and non-menthol cigarette preferring smokers Aim 2 is to establish a dose-effect curve positive subjective effects and alleviation of smoking urges as a function of nicotine delivery rate. Aim 3 is to establish a dose-effect curve for nicotine's effect to alleviate symptoms of nicotine withdrawal in abstinent smokers as a function of nicotine delivery rate. Aim 4 is to establish a dose-effect curve for nicotine's acute cardiovascular health effects. Data from this project will help to establish benchmark values for nicotine's threshold effects that will guide policies on the nicotine yield of tobacco products. Presented is the time frame at which the peak change was strongest by treatment arm. The possible peak numbers could be 1, 3, 5, 7 and 10 minutes."
BACKGROUND: Postoperative pain (PP) is a dynamic process that reflects the complex interplay between symptoms, treatment, and patient experiences, and its intensity is reportedly primarily related to the severity of surgical trauma. However, no large-scale national database-based study has hitherto been conducted to assess the occurrence and features related to PP following breast cancer (BC) surgery.
METHODS: In this retrospective analysis, we screened BC surgery cases between 2015 and 2019 within the National Inpatient Sample (NIS) Database, utilizing the International Classification of Diseases (ICD) 10th edition clinical modification codes. The researchers identified patients who developed PP and compared them to those who did not. Factors associated with PP were then screened: patient demographics (age and race), hospital characteristics (type of insurance, bed size, teaching status, type of admission, location, and hospital area), length of stay (LOS), total cost during hospitalization, inpatient mortality, comorbidities, and perioperative complications. Data were analyzed using descriptive statistics. Multivariate logistic regression analysis was used to determine the independent risk factors for postoperative pain in BC surgery.
RESULTS: 39,870 BC surgery cases were identified over a five-year period from 2015 to 2019. The overall occurrence of PP following breast cancer surgery was 6.15% (2,387 cases), with a slight upward trend every year. Significant racial disparities were observed, Whites associated with a higher incidence of PP (P < 0.001). In addition, the incidence of elective admission was 11.96% lower (67.491% vs. 79.451%) than that of patients without PP following breast cancer surgery (P < 0.001). Besides, PP was related to prolonged hospitalization duration (3 vs. 2 days; P < 0.001), and higher total cost ($68,283 vs. $60,036; P < 0.001). Multivariate logistic regression identified breast cancer surgery-independent risk factors for PP, including younger age, non-elective hospital admission, rural hospitals, depression, drug abuse, metastatic cancer, psychoses, weight loss, and chronic pulmonary disease. In addition, postoperative pain for BC was associated with urinary retention, gastrointestinal complications, continuous invasive ventilation, deep vein thrombosis, urinary tract infection, blood transfusion, arrhythmia, and chest pain.
CONCLUSION: Despite the low incidence of postoperative pain in BC surgery cases, it is essential to investigate factors predisposing to PP to allow optimal care management and improve the outcomes of this patient population.
BACKGROUND: There is limited evidence that beta-blockers may provide benefit for patients with moderate-severe traumatic brain injury (TBI) during the acute injury period. Larger studies on utilization patterns and impact on outcomes in clinical practice are lacking.
OBJECTIVE: The present study uses a large, national hospital claims-based dataset to examine early beta-blocker utilization patterns and its association with clinical outcomes among critically ill patients with moderate-severe TBI.
METHODS: We conducted a retrospective cohort study of the administrative claims Premier Healthcare Database of adults (≥17 years) with moderate-severe TBI admitted to the intensive care unit (ICU) from 2016 to 2020. The exposure was receipt of a beta-blocker during day 1 or 2 of ICU stay (BB+). The primary outcome was hospital mortality, and secondary outcomes were: hospital length of stay (LOS), ICU LOS, discharge to home, and vasopressor utilization. In a sensitivity analysis, we explored the association of beta-blocker class (cardioselective and noncardioselective) with hospital mortality. We used propensity weighting methods to address possible confounding by treatment indication.
RESULTS: A total of 109 665 participants met inclusion criteria and 39% (n = 42 489) were exposed to beta-blockers during the first 2 days of hospitalization. Of those, 42% received cardioselective only, 43% received noncardioselective only, and 14% received both. After adjustment, there was no association with hospital mortality in the BB+ group compared to the BB- group (adjusted odds ratio [OR] = 0.99, 95% confidence interval [CI] = 0.94, 1.04). The BB+ group had longer hospital stays, lower chance of discharged home, and lower risk of vasopressor utilization, although these difference were clinically small. Beta-blocker class was not associated with hospital mortality.
CONCLUSION: In this retrospective cohort study, we found variation in use of beta-blockers and early exposure was not associated with hospital mortality. Further research is necessary to understand the optimal type, dose, and timing of beta-blockers for this population.
Nijmegen breakage syndrome (NBS) is a DNA repair disorder. The only curative option for combine immunodeficiency in NBS is allogeneic hematopoietic stem cell transplantation (HSCT). Standard myeloablative conditioning regimens in DNA repair disorders lead to increased morbidity and mortality after HSCT. Low doses of alkylators are used to reduce toxicity rates, which, however, increase the risks of mixed chimerism and graft failure. The data of treosulfan usage in NBS are sparse. To evaluate the safety and efficacy of low dose treosulfan based conditioning regimen in NBS, treosulfan 21g/m2 in combination with fludarabine 150mg/mg, thymoglobulin (Genzyme) 5mg/kg and rituximab 100mg/m2 will be used from day -6 to -1 day, followed by stem cell infusion and post-transplant cyclophosphamide 25mg/kg/day (+3,+4 day) for GVHD prophylaxis. The primary endpoint is event-free survival, where graft failure, death, and malignancies are considered as events.
The invention discloses a compound zinc undecylenate triamcinolone acetonide ointment and a preparation method thereof. The invention relates to the field of medicine. The compound zinc undecylenate triamcinolone acetonide ointment provided by the invention is composed of zinc undecylenate, undecylenic acid, triamcinolone acetonide acetate, and an emulsion substrate. Compared to existing technologies, the preparation method is advantaged in controllable temperature and simple formula, and the product is advantaged in good characters. With the added triamcinolone acetonide acetate, comprehensive inflammation resisting and allergy resisting effects of the medicine are stronger and more durable. The product and the method are especially suitable for industrial productions.
In Part I of this series, we provide guidance for preparing a systematic review protocol. In this article, we highlight important steps and supplement with exemplars on conducting and reporting the results of a systematic review. We suggest how authors can manage protocol violations, multiplicity of outcomes and analyses, and heterogeneity. The quality (certainty) of the evidence and strength of recommendations should follow the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) approach. It is our goal that Part II of this series provides valid guidance to authors and peer reviewers who conduct systematic reviews to adhere to important constructs of transparency, structure, reproducibility, and accountability. This will likely result in more rigorous systematic reviews being submitted for publication to the journals like Regional Anesthesia & Pain Medicine and Anesthesia & Analgesia .
The present invention relates to the field of biotechnology, and relates to an EZH2 alternative splicing site and an application thereof. Two subtypes, i.e., EZH2-L and EZH2-S, are separately knocked down using specific siRNA, and myocardial hypertrophy and heart failure models are separately built at the cell level and at the animal level. The result shows that, after EZH2-L is knocked down, the expression level of a myocardial hypertrophy pathological gene is significantly reduced, the myocardial cell area is reduced, and the weight of the heart is reduced; and after EZH2-S is knocked down, the expression level of the myocardial hypertrophy pathological gene is significantly increased, the myocardial cell area is increased, and the weight of the heart is increased. It indicates that EZH2-L and EZH2-S have the effects of promoting and inhibiting myocardial hypertrophy and heart failure, respectively. In addition, after EZH2-L is knocked down, proliferation of tumor cells is inhibited, and the knockdown of EZH2-S has no effect on proliferation of the tumor cells. New targets and new strategies are provided for research and development of drugs for treating EZH2 gene-related diseases.
1433593 Enzyme lectin conjugates ROYAL COLLEGE OF SURGEONS and MEDICAL RESEARCH COUNCIL 4 June 1973 [9 June 1972] 27048/72 Heading C3H [Also in Division A5] Substances useful in treating dental diseases are made by conjugating a therapeutic agent with a lectin capable of combining with dental plaque. The preferred lectin is concanavalin and the therapeutic agent may be an enzyme, e.g. a dextranose, levanase, amylase or catalase, an antibiotic, e.g. vanoomycin, ampicillin, bacitracin or erythromycin, or a protein (e.g. serum albumin) complexed with a fluoride. The conjugates may be prepared by conventional chemical procedures, using, e.g., diazosulphanilic acid, glutardialdehyde, the diazonium salt of o - dianisidine as coupling agent or by separately thiolating the therapeutic agent and the lectin, e.g. with N-acetyl cysteine (or N- acetyl homocysteine) thiolactone and oxidizing the thiolated products together to form a disulphide bridge between them. Reference is also made to coupling the lectin to dextranase using toluene 2,4-diisocyanate.
PURPOSE:To efficiently remove white blood cells and microagglutinated matter in a short period of time without clogging the filter regardless of the preservative condition of concentrated red blood cells, by specifying the product of the average fiber diameter and average interfiber spacing of white blood cell capturing filter media to a specific range. CONSTITUTION:At least 3 kinds are required for the filter media consisting of fibrous materials. One filter medium A satisfies the mathematical expression 7>=XY when the average fiber diameter is designated as X(mum) and the average interfiber spacing is expressed by equation (1) as Y(mum). The filter medium A corresponds to the filter consisting of extremely fine fibers and is capable of efficiently capturing the white blood cells in the concentrated red blood cells, particularly the entire part of the white blood cells including lymphocytes which are considered to be difficult to capture. The 2nd filter medium B satisfies the mathematic expression 50>=XY>7 and is the filter for capturing the relatively small microagglutinated matter slightly larger than the white blood cells. The final filter medium C satisfies the mathematical expression XY>50. This filter medium C is the filter which is further larger in the average fiber diameter and/or the average interfiber spacing than the filter medium B and captures such larger microagglutinated matter which clogs the filter medium B.
Hepatic metabolism is the major route of anagrelide clearance. Exposure to anagrelide is increased 8-fold in patients with moderate hepatic impairment [see Clinical Pharmacology (12.3)] and dose reduction is required [see Dosage and Administration (2.3)]. Use of anagrelide in patients with severe hepatic impairment has not been studied. Avoid use of anagrelide in patients with severe hepatic impairment. The potential risks and benefits of anagrelide therapy in a patient with mild and moderate hepatic impairment should be assessed before treatment is commenced. Assess hepatic function before and during anagrelide treatment [see Warnings and Precautions (5.1)].
Sevoflurane induction and maintenance were selected. Intubation was performed after lidocaine spray on vocal cord. After that, an effective caudal or brachial plexus block was performed. End-tidal concentration of sevoflurane was maintained at 2.5%. Spontaneous respiratory was maintained. Sevoflurane was stopped after the end of surgery. Patients were randomly assigned to 2 groups: high concentration group (Group HC, end-tidal concentration of sevoflurane when extubating \>=0.5%) and low concentration group (Group LC, end-tidal concentration of sevoflurane when extubating \<0.5%). Patients in Group LC were extubated when they coughed or purposeful movement appeared. The patients whose end-tidal concentration of sevoflurane \>= 0.5% were excluded. Patients in Group HC were extubated when any of the criteria was met: 1.the patient coughed or purposeful movement appeared 2.end-tidal concentration of sevoflurane decreased to 0.5%. A trained nurse (blind to groups) recorded PAEDs scores in PACU.
Megestrol acetate is a synthetic, antineoplastic and progestational drug. Megestrol acetate is a white, crystalline solid chemically designated as 17(alpha)-(acetyloxy)-6-methylpregna-4,6-diene-3,20-dione. Solubility at 37°C in water is 2 mcg per mL, solubility in plasma is 24 mcg per mL. Its molecular weight is 384.51. The molecular formula is C 24H 32O 4 and the structural formula is represented as follows: 

Megestrol acetate is supplied as tablets for oral administration containing 20 mg and 40 mg megestrol acetate.

Megestrol acetate tablets contain the following inactive ingredients: acacia spray dried, colloidal silicon dioxide, corn starch, di-calcium phosphate dihydrate powder, lactose hydrous impalpable, magnesium stearate and pregelatinized starch.